SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs rally is being tied to expectations that Metas Muse and other AI agents will increase demand for CPUs alongside GPUs, adding to optimism around AI infrastructure. Traders are largely bullish and cite momentum and a short squeeze, while others warn the surge has outrun fundamentals and leaves the stock vulnerable to a pullback.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns earnings outlook is the central focus, with traders weighing whether AI-driven HBM and DRAM demand, tight supply, and stronger memory pricing can sustain growth. Bulls see room for continued gains, while skeptics point to high expectations, memory-market cyclicality, and the Netlist patent investigation as risks.

Akamai Technologies, Inc. is the cybersecurity and cloud computing company that powers and protects business online. The market security solutions, superior threat intelligence, and global operations team provide defense in depth to safeguard enterprise data and applications everywhere. The firm full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. The global enterprises trust Akamai to provide the industry reliability, scale, and expertise they need to grow their business with confidence. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Traders are citing fears that Anthropics Claude and managed-agent products could disrupt established CDN and cybersecurity providers, as Akamai has fallen alongside peers Cloudflare and Fastly. The decline is also being discussed as a pullback after the Anthropic contract rally, with some traders focused on the deals capital-spending and dilution risks.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

A sharp rally is drawing attention, with traders pointing to Ondos BlackRock-powered tokenized portfolios and broader real-world-asset tokenization momentum. Some remain cautious that ONDO is primarily a governance token and may not share in protocol revenue unless a fee switch or other value-accrual mechanism is introduced.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions milestone of entangling 30 logical qubits on its commercial Sqale system using 80 physical qubitssupported by an AI-assisted reduction in gate requirementsis driving attention and optimism about its path toward scalable quantum computing. Many traders view the achievement as technical validation, while others say the share-price response has been muted and debate whether the news is already priced in.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quants Robinhood listing is the main catalyst behind the sharp rally, with traders anticipating broader access and renewed momentum. Bullish posts also point to Quants banking and tokenization use cases and limited supply, while skeptics warn the move could fade or retrace.

FuboTV, Inc. is a consumer-first live TV streaming company with the mission of delivering premium sports, news and entertainment programming that offers greater choice, flexibility and value. The company was founded by David Gandler, Alberto Horihuela Suarez, and Sung Ho Choi on February 20, 2009 and is headquartered in New York, NY.

fuboTV Inc - Ordinary Shares - Class A

fuboTV Inc

Wedbushs reiterated bullish view, tied by traders to Disney integration and subscriber growth, is a focal point, but the stocks pullback after a sharp run has overshadowed it. The community is split between expecting short covering to fuel another rebound and viewing FUBOs volatile price action and business outlook as bearish.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Solar-sector weakness and Enphases continued share-price slide are the main focus, with traders pointing to interest-rate sensitivity and a pressured residential-solar market. Some expect further downside, while others are buying dips and citing the companys longer-term IQ SST/data-center opportunity as a potential growth driver.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Goldman Sachs return to a Buy rating, citing easing Amtagvi launch hurdles and improving margins, is the main catalyst behind IOVAs rally. Traders are upbeat but some question Goldmans sharp reversal, while attention remains on the pending revenue-guidance update and NSCLC data.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

A sharp price breakout has sparked bullish momentum, with traders celebrating the move while some caution that resistance could still trigger a rejection. Optimism is also tied to the anticipated AerodromeVelodrome merger and expansion to Ethereum, though traders are watching for execution and follow-through.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.read more...

Arbutus Biopharma Stock Rises 11% On Launch Of $230 Mln Share Buyback

(RTTNews) - Shares of Arbutus Biopharma Corporation (ABUS) are gaining about 11 percent on Friday morning after the company announced its plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent s...

Arbutus Biopharma Launches $230 Mln Share Buyback Via Dutch Auction; Shares Up In Pre-market

(RTTNews) - Arbutus Biopharma Corp. (ABUS) Friday announced a plan to repurchase up to $230 million of its common shares through a modified Dutch Auction tender offer, returning proceeds from its recent settlement with Moderna to shareholders...

ABUS Stock Surges 10% Today — What’s Driving This Super Rally?

Equity

Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.


MRNA Q2 Earnings Meet, Stock Down on Norovirus Vaccine Setback

Moderna's Q2 revenue tops estimates, but shares fall after its phase III norovirus vaccine study misses early success criteria.

ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?

On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.


ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week

Arbutus expects to receive around $179 million from Moderna. 


Moderna's Revenues See Strong International Momentum in Q1 Earnings

MRNA's Q1 revenues soar 260% on strong international vaccine sales, while cost cuts and new EU approvals support its broader growth strategy.

QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopharma among other stocks also falling.read more...

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Here's Why

Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - What's Next...

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.02	--	--	N/A
Q2 '26	-$0.02	-$0.03	-50.00%	MISSED
Q1 '26	-$0.03	$0.87	3000.00%	BEAT
Q4 '25	-$0.04	-$0.01	71.47%	BEAT
Q3 '25	-$0.03	-$0.04	-33.33%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

ABUS Earnings

Upcoming Earnings: Q3 '26

Historical Earnings